GLP-1 Medication Shortage Update: What Patients Need to Know in 2025

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan.

Current Shortage Status (2025)

The GLP-1 medication supply crisis that began in earnest in 2022 and dominated patient and prescriber conversations through 2023 and 2024 has substantially resolved as of early 2025. The FDA removed semaglutide — the active ingredient in Ozempic and Wegovy — from its official drug shortage list in February 2025, following a similar move for tirzepatide (Mounjaro and Zepbound) in late 2024. This marks a turning point after years during which millions of patients struggled to obtain medications they had been prescribed and were benefiting from.

The resolution of the shortage is the result of massive manufacturing capacity investments by both Novo Nordisk and Eli Lilly, the makers of semaglutide and tirzepatide respectively. Both companies announced multi-billion dollar expansions of their fill-and-finish manufacturing infrastructure, added new production facilities in Europe and the United States, and streamlined their supply chains to reduce the bottlenecks that had caused the initial crisis. Novo Nordisk in particular committed over $6 billion in new manufacturing investments over a three-year period specifically to address semaglutide supply constraints.

That said, "shortage resolved" at the national level does not always translate immediately to "available at your local pharmacy." Supply chain dynamics mean that distribution can be uneven, with some regions, pharmacy chains, and specific dose strengths seeing continued constraints even as the overall picture has improved. Patients should not assume that because the FDA has removed these drugs from its shortage list, their specific pharmacy will have their specific dose in stock at all times.

The FDA's drug shortage database is updated regularly and remains the most authoritative official source on national supply status. The database is publicly accessible at fda.gov/drugs/drug-safety-and-availability/ drug-shortages and is searchable by drug name. For real-time community intelligence on local pharmacy availability, patient communities on Reddit (r/Ozempic, r/WegovyWeightLoss, r/tirzepatide) and condition-specific Facebook groups often have more up-to-date information than official sources, as members actively share which pharmacies have stock.

Ozempic and Wegovy Availability

Semaglutide in its injectable form — marketed as Ozempic for type 2 diabetes management and Wegovy for chronic weight management — is now broadly available across most dose strengths in the United States. The most critical improvement has been in the availability of higher-dose pens: the 1 mg and 2 mg doses of Ozempic, and the 1.7 mg and 2.4 mg doses of Wegovy, which were among the most severely constrained during the shortage period.

Novo Nordisk has significantly increased its U.S. distribution capacity and has been fulfilling wholesaler orders more reliably since mid-2024. The company reports that it is now manufacturing more doses of semaglutide per month than at any previous point in the drug's history, and that it has reduced lead times for pharmacy restocking substantially. For most patients at major pharmacy chains — CVS, Walgreens, Walmart Pharmacy, and Costco — Ozempic and Wegovy should be routinely fillable with advance planning of five to seven days.

Rybelsus, the oral form of semaglutide approved for type 2 diabetes, has generally been less affected by supply constraints throughout this period, as it uses a different manufacturing process. Oral semaglutide remains available across its three dose strengths (3 mg, 7 mg, and 14 mg) at most pharmacies. For patients with type 2 diabetes who experienced persistent supply issues with injectable semaglutide, Rybelsus may be a practical bridge if prescribing criteria are met — a conversation worth having with your prescriber.

Independent and smaller pharmacy chains may still experience more variability in semaglutide availability due to their smaller ordering volumes and less favorable wholesaler priority. If you consistently have trouble filling at a local independent pharmacy, shifting to one of the major national chains — even if less convenient — may solve the problem. Some patients have also found success with mail-order pharmacy services, which can order larger quantities and have more predictable stock levels.

One remaining caveat: Wegovy starter dose pens (0.25 mg and 0.5 mg) are in particularly high demand as new patients begin therapy and may experience shorter intermittent stock-outs even now that the broader shortage is resolved. If you are starting Wegovy for the first time, ask your prescriber to send the prescription to your pharmacy electronically well in advance of when you need it, and call the pharmacy two to three days before you plan to pick it up to confirm availability.

Mounjaro and Zepbound Status

Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, was removed from the FDA's drug shortage list in October 2024 following significant improvements in Eli Lilly's manufacturing output. The company had been investing heavily in its injectable drug manufacturing capacity since 2022 and accelerated those investments after tirzepatide's weight management approval brought demand far exceeding initial projections.

The resolution of the tirzepatide shortage is particularly significant because tirzepatide's unique dual mechanism — acting on both GLP-1 and GIP receptors — produces greater average weight loss than semaglutide and has a distinct side effect profile that some patients tolerate better. During the shortage, many patients who had been doing well on tirzepatide were forced onto semaglutide as a substitute, often with suboptimal results. The improved availability means that patients and prescribers can now make drug selection decisions based on clinical appropriateness rather than simply what is available.

Eli Lilly also introduced Zepbound single-dose vials — available in 2.5 mg and 5 mg doses — at a lower list price point ($349 per month) as part of its strategy to expand patient access. These vials, intended to be used with separate syringes, represent a meaningful cost reduction compared to the standard auto-injector pens and have been broadly welcomed by patients paying out of pocket. Availability of the vials has been good since launch, though the auto-injector pens remain the more commonly dispensed form.

Despite the overall improvement, some specific tirzepatide doses — particularly the 10 mg and 12.5 mg maintenance doses — can still be intermittently constrained at the local pharmacy level. If you are titrating up and approaching a higher dose, planning ahead by calling your pharmacy a week before you need your next dose is prudent. If your pharmacy is out of stock, many pharmacy management systems allow them to check stock at nearby branches of the same chain, which can save significant time.

What the Shortage End Means for Compounding

The most significant policy consequence of the FDA removing semaglutide and tirzepatide from the drug shortage list is the impact on compounding pharmacies. Under federal law, FDA-registered outsourcing facilities and traditional compounding pharmacies are permitted to compound copies of drugs that appear on the FDA's official shortage list, without individual patient-specific prescriptions in the case of outsourcing facilities. Once a drug is removed from the shortage list, this legal justification disappears.

In March 2025, the FDA sent letters to outsourcing facilities and issued guidance confirming that the compounding of semaglutide and tirzepatide was no longer permissible now that the shortage status had been resolved. This effectively shut down the large-scale commercial compounding of these drugs — a market that had grown to hundreds of millions of dollars annually, serving patients through telehealth platforms and online pharmacies at significantly lower prices than branded products.

For patients who had been relying on compounded semaglutide or tirzepatide — often purchased through telehealth services for $150 to $400 per month compared to $900 to $1,300 for brand-name products — this represents a significant disruption. The transition back to branded medications may require new prior authorization approvals from insurance if the patient was previously self-paying, changes to dosing (branded products have specific pen doses, while compounded versions often allowed custom dosing), and potentially significant cost increases.

Traditional compounding pharmacies — those compounding for specific patients with documented clinical needs, such as a patient who is allergic to an excipient in the branded formulation — may still be able to compound semaglutide and tirzepatide on a patient-specific basis under the 503A provisions of the Drug Quality and Security Act. However, this is a much narrower pathway and requires documented medical necessity, not simply a preference for a lower cost option.

Patients who have been on compounded GLP-1 medications and are now transitioning to branded products should be aware that dosing equivalence is not guaranteed. Compounded formulations varied considerably between providers in terms of concentration, excipients, and delivery methods. Work with your prescriber to establish an appropriate starting dose on the branded product and monitor your response closely, particularly in the first month of the transition.

What to Do If You Can't Get Your Medication

Despite the overall improvement in supply, some patients will continue to encounter local or temporary availability challenges. The most effective first step is to call multiple pharmacies in your area — not just the one where you routinely fill prescriptions. Major chains like CVS, Walgreens, Walmart, Costco, and Rite Aid all carry GLP-1 medications, and stock can vary considerably from location to location even within the same chain. Many pharmacies will tell you over the phone whether they have a medication in stock before you transfer your prescription.

Mail-order pharmacies affiliated with your insurance plan can be an excellent option for stable patients who are not mid-titration. Mail-order pharmacies typically dispense 90-day supplies, which can significantly reduce the frequency of refill hassles. They often have better and more consistent stock levels than retail pharmacies because they order in larger volumes and are less subject to the spot-availability fluctuations that affect brick-and-mortar locations.

Specialty pharmacies — particularly those affiliated with large health systems — sometimes have better access to medications that are in high demand. If your prescriber is part of a large hospital system or multispecialty group, ask if they can route your prescription to an in-system specialty pharmacy. These pharmacies often have direct relationships with manufacturers and can sometimes obtain stock that retail pharmacies cannot.

Both Novo Nordisk and Eli Lilly offer patient assistance programs for uninsured or underinsured patients. Novo Nordisk's Patient Assistance Program provides Ozempic and Wegovy at no cost to qualifying patients who meet income eligibility criteria. Eli Lilly's LillyAnswers program provides Mounjaro and Zepbound similarly. If cost or access is a barrier, contact the manufacturer directly — the phone numbers for these programs are on the official product websites — or ask your prescriber's office to help you apply.

If you need to pause your GLP-1 medication due to genuine unavailability, contact your prescriber immediately. Brief interruptions of one to two weeks are unlikely to result in significant clinical setback for most patients, but longer gaps can affect blood sugar control in patients with diabetes and may result in some weight regain. Your prescriber may want to adjust other diabetes medications temporarily during a gap in GLP-1 therapy. They can also help document the supply issue, which may be useful for insurance purposes if you need to justify the gap.

How to Stay Informed

The landscape for GLP-1 medications continues to evolve rapidly — in terms of availability, regulatory status, coverage policies, and the pipeline of new agents. Staying informed requires drawing from multiple sources, as no single resource captures the full picture. The FDA's drug shortage database at fda.gov is the authoritative official source for national shortage status. Bookmark it and check it periodically if supply remains a concern for you.

Your prescriber's office is often the most reliable practical source for local availability information. Practices that prescribe high volumes of GLP-1 medications typically develop a good understanding of which pharmacies in the area reliably stock which products, and their staff can often point you in the right direction without requiring a full appointment. Do not hesitate to contact their office specifically about supply questions — it is a common request they are well-equipped to handle.

Patient advocacy organizations, including the Obesity Medicine Association and the American Diabetes Association, issue periodic updates on GLP-1 supply and coverage developments through their public websites and email newsletters. Subscribing to updates from one or both of these organizations is worthwhile if GLP-1 therapy is a significant part of your health management.

Health journalism outlets that cover the pharmaceutical industry — STAT News, Fierce Pharma, and Reuters Health — provide timely coverage of manufacturing developments, regulatory actions, and supply chain news related to GLP-1 drugs. While these publications are written primarily for industry audiences, their news coverage is publicly accessible and generally reliable. Setting up Google Alerts for terms like "semaglutide supply" or "tirzepatide shortage" can also surface relevant news as it breaks.

Finally, your pharmacist is an underutilized resource. Pharmacists are on the front lines of supply chain issues and often know about regional trends in availability before prescribers do. Building a relationship with your pharmacist — especially if you use a smaller independent pharmacy where staff continuity is higher — means you may get proactive alerts when restocking is delayed, allowing you to plan ahead rather than discovering a problem when you arrive to pick up your prescription.